Stock fact sheet · data as of
LENSAR Inc (LNSR): fair value, margin of safety and Wheel Score
Healthcare · Medical - Devices · United States · Value
Is LNSR undervalued?
At 6.03 (close of 16 Oct 2026), LNSR trades 90% below the GLS average fair value of 61.47. That average comes from 5 models run on the latest filings, and 5 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns LENSAR Inc the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between Graham Number (8.77) and Graham Growth (161.39). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files LNSR under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for LNSR
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 8.77 | +45% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 161.39 | +2576% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 70.54 | +1070% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 35.32 | +486% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 31.35 | +420% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -4.12 | -168% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 12.00 | +99% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
LENSAR Inc scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 2.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 147.2%, ROE 131.7%, ROA -48.0% - with debt at -0.11 times equity and negative free cash flow.
LENSAR Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 89%, Service 11% (quarter Q2 FY2026).
Institutional ownership scores 5/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 147.2% |
|---|---|---|---|
| GLS Moat | 2.5 / 10 | ROE | 131.7% |
| Debt / equity | -0.11 | ROA | -48.0% |
| Free-cash-flow yield | -9.9% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 57: Fair
A Wheel Score of 57 puts LENSAR Inc in the Fair band - below the 70 the Sunday Scan requires. Value 25/25, Health 11/20, Moat 4/15, Premium 11/20 and Stability 6/20; the weakest part is Moat (4/15).
Implied volatility is 94% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (11 of 20) because volatility this high usually comes with a reason. Chain open interest is 6,255 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 41k shares a day on a market cap of $74M, with a beta of 0.94; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 90% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 4 / 15 | moat 2.5/10 | |
| Premium | 11 / 20 | implied volatility 94% | |
| Stability | 6 / 20 | 41k shares/day, $74M cap, beta 0.94 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 12 Nov 2026 (before the open), 27 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Devices
The 12 companies below are the closest to LENSAR Inc by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| EBRCZ EBR Systems, Inc. | 0.1148 | - | - | 29No options | $73M |
| RTGN RetinalGenix Technologies Inc. | 3.99 | - | - | 25No options | $75M |
| ECOR electroCore, Inc. | 8.35 | - | - | 28No options | $75M |
| OM Outset Medical, Inc. | 4.08 | - | - | 30Weak | $77M |
| HYPR Hyperfine, Inc. | 0.7801 | - | - | 42Weak | $71M |
| LUNG Pulmonx Corporation | 1.85 | - | - | 36Weak | $79M |
| SERA Sera Prognostics, Inc. | 2.07 | - | - | 32Weak | $80M |
| MBOT Microbot Medical Inc. | 0.9500 | 0.0728 | -1205% | 25Weak | $64M |
| LUCD Lucid Diagnostics Inc. | 0.5201 | - | - | 36No options | $99M |
| MYO Myomo, Inc. | 1.30 | - | - | 31Weak | $51M |
| COCH Envoy Medical, Inc. | 0.6447 | 0.0239 | -2603% | 11No options | $50M |
| TELA TELA Bio, Inc. | 1.10 | 1.19 | +8% | 36Weak | $49M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about LNSR
Is LNSR undervalued right now?
By the GLS models, yes: at 6.03 the stock is 90% below the average fair value of 61.47 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of LNSR and what does it mean?
LNSR scores 57 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for LNSR?
61.47 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does LENSAR Inc report earnings next?
The next earnings report is due on 12 Nov 2026 (before the open), 27 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does LNSR have listed options, and how liquid are they?
Yes. The nightly snapshot found 64 listed contracts with 6,255 open interest across all expiries and implied volatility of 94% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.